About
About ClinicalInvestor
Making clinical-stage biotech investing accessible to everyone, not just Wall Street insiders.
Our Mission
Biotech stocks move on clinical data, FDA decisions, and scientific catalysts that most investors find impossible to track. ClinicalInvestor exists to change that.
We aggregate, structure, and explain the events that drive biotech stock prices so you can make informed decisions without a PhD in pharmacology.
What We Provide
Catalyst Calendar
Every FDA decision date, clinical trial readout, and biotech conference tracked and explained in plain English.
Company Profiles
Pipeline breakdowns, upcoming catalysts, and competitive landscape analysis for clinical-stage biotech companies.
Educational Guides
Step-by-step guides on reading clinical trial data, understanding FDA processes, and evaluating biotech stocks.
Trial Translator
Our free tool that pulls live ClinicalTrials.gov data and applies a rules-based investor checklist to break down trial results in plain English.
Our Data Sources
Accuracy matters when money is on the line. Our data is sourced from official public filings, regulatory databases, and company press releases:
FDA: PDUFA dates, approval letters, Complete Response Letters, Advisory Committee schedules
SEC: 10-K/10-Q filings, 8-K material events, S-1 prospectuses
ClinicalTrials.gov: Trial registrations, status updates, result postings
Company IR: Press releases, investor presentations, earnings transcripts
Frequently asked questions
- What is ClinicalInvestor?
- ClinicalInvestor is a free biotech intelligence platform for retail investors. We combine AI-powered clinical trial analysis, a daily catalyst calendar, and research profiles for clinical-stage biotech companies to help individual investors understand the science and the stocks.
- Is ClinicalInvestor free to use?
- Yes. All core tools — the catalyst calendar, company profiles, Trial Translator, and educational guides — are free and require no signup.
- Where does ClinicalInvestor get its data?
- We aggregate data from official public sources: the FDA (PDUFA dates, AdCom schedules, approval letters), the SEC (10-K/10-Q/8-K filings), ClinicalTrials.gov, and company investor-relations releases.
Important Disclaimer
ClinicalInvestor is an educational resource, not a financial advisor. Nothing on this site constitutes personalized investment advice. Biotech investing carries substantial risk. Always do your own due diligence and consider consulting a licensed financial professional before making investment decisions.
See also our editorial policy and disclosures.
Get In Touch
Have feedback, a correction, or a suggestion? We want to hear from you. Reach us at hello@clinicalinvestor.com.